What could you do if your data was working for you and not against you? With Bloomberg delivering

enterprise data directly to your systems, you get easy access to the details you want, optimized for

higher level analysis, and financial data experts committed to helping you maximize your every move.

Our data is made for more, so you can show the world what you're made of.

Visit Bloomberg.com slash enterprise data to learn more.

Welcome to Prognosis. I'm Laura Carlson. It's day 298 since coronavirus was declared a global pandemic.

Today's main story, as states struggle to piece together vaccine strategies without a coordinated national plan, some have resorted to web-based technology for logistical support. The result? They're

lining up appointments using software that's better suited for arranging volleyball meetups

than a historic public health campaign. But first, here's what happened in virus news today.

Modernist COVID-19 vaccine won the backing of the drug regulator in the European Union.

That clears the way for a second weapon to stem the virus's winter resurgence in Europe.

EU leaders are facing growing pressure to speed up clearance and deployment of vaccines

as cases surge across the continent.

The 27-Nation block began immunizations last week with the Pfizer vaccine.

But the pace of the rollout has been uneven.

In England, more than 1 million people now have coronavirus.

That's according to UK Prime Minister Boris Johnson,

who unveiled official statistics from a government report on Wednesday.

Rocketing case rates from the new virus strain mean one person in every 50 in England now has the illness.

In London, the number is 1 in 30. Johnson vowed to speed up the government's vaccination

program in order to eventually lift the latest lockdown. Finally, experts advising the

World Health Organization on vaccine policies recommended against spreading the interval between two

...